Cargando…

Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study

BACKGROUND: Venous thromboembolism is a significant source of morbidity and mortality following total hip replacement and total knee replacement. Apixaban has been proven to be efficacious without increased risk of bleeding in phase-III trials in patients undergoing total knee replacement and total...

Descripción completa

Detalles Bibliográficos
Autores principales: Panchal, Himanshu, Agashe, Abhijit, Sancheti, Parag K, Kulkarni, Namrata B, Taur, Santosh R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511912/
https://www.ncbi.nlm.nih.gov/pubmed/34659763
http://dx.doi.org/10.1177/20503121211049962
_version_ 1784582865697112064
author Panchal, Himanshu
Agashe, Abhijit
Sancheti, Parag K
Kulkarni, Namrata B
Taur, Santosh R
author_facet Panchal, Himanshu
Agashe, Abhijit
Sancheti, Parag K
Kulkarni, Namrata B
Taur, Santosh R
author_sort Panchal, Himanshu
collection PubMed
description BACKGROUND: Venous thromboembolism is a significant source of morbidity and mortality following total hip replacement and total knee replacement. Apixaban has been proven to be efficacious without increased risk of bleeding in phase-III trials in patients undergoing total knee replacement and total hip replacement. Due to paucity of data on safety of apixaban in Indian patients, this phase-IV study was conducted to evaluate safety of apixaban in patients undergoing total knee replacement and total hip replacement. METHODS: In this non-comparative phase-IV clinical trial, patients undergoing elective total knee replacement or total hip replacement surgery, or a revision of at least one component of total knee replacement or total hip replacement, were enrolled. The eligible patients were given the approved dosage of apixaban 12 to 24 h after completing the skin wound closure. The primary safety outcome was the composite of the International Society on Thrombosis and Haemostasis–defined major bleeding and clinically relevant non-major bleeding events at the end of the treatment. The secondary efficacy endpoint was the composite of venous thromboembolism/all-cause death at the end of the treatment. RESULTS: A total of 498 patients received apixaban prophylaxis therapy. Six (1.2%) bleeding adverse events were observed during the treatment period. Only one bleeding event was adjudicated as an International Society on Thrombosis and Haemostasis–defined clinically relevant non-major bleeding event (moderate severity). There were no fatal bleeding events and no deaths following the treatment. One venous thromboembolism event, that is, symptomatic distal left leg DVT, was reported in a total knee replacement patient and was adjudicated during the treatment period. CONCLUSION: Apixaban demonstrated a favorable safety profile for venous thromboembolism prevention in Indian patients undergoing total knee replacement or total hip replacement.
format Online
Article
Text
id pubmed-8511912
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85119122021-10-14 Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study Panchal, Himanshu Agashe, Abhijit Sancheti, Parag K Kulkarni, Namrata B Taur, Santosh R SAGE Open Med Original Research Article BACKGROUND: Venous thromboembolism is a significant source of morbidity and mortality following total hip replacement and total knee replacement. Apixaban has been proven to be efficacious without increased risk of bleeding in phase-III trials in patients undergoing total knee replacement and total hip replacement. Due to paucity of data on safety of apixaban in Indian patients, this phase-IV study was conducted to evaluate safety of apixaban in patients undergoing total knee replacement and total hip replacement. METHODS: In this non-comparative phase-IV clinical trial, patients undergoing elective total knee replacement or total hip replacement surgery, or a revision of at least one component of total knee replacement or total hip replacement, were enrolled. The eligible patients were given the approved dosage of apixaban 12 to 24 h after completing the skin wound closure. The primary safety outcome was the composite of the International Society on Thrombosis and Haemostasis–defined major bleeding and clinically relevant non-major bleeding events at the end of the treatment. The secondary efficacy endpoint was the composite of venous thromboembolism/all-cause death at the end of the treatment. RESULTS: A total of 498 patients received apixaban prophylaxis therapy. Six (1.2%) bleeding adverse events were observed during the treatment period. Only one bleeding event was adjudicated as an International Society on Thrombosis and Haemostasis–defined clinically relevant non-major bleeding event (moderate severity). There were no fatal bleeding events and no deaths following the treatment. One venous thromboembolism event, that is, symptomatic distal left leg DVT, was reported in a total knee replacement patient and was adjudicated during the treatment period. CONCLUSION: Apixaban demonstrated a favorable safety profile for venous thromboembolism prevention in Indian patients undergoing total knee replacement or total hip replacement. SAGE Publications 2021-10-07 /pmc/articles/PMC8511912/ /pubmed/34659763 http://dx.doi.org/10.1177/20503121211049962 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Panchal, Himanshu
Agashe, Abhijit
Sancheti, Parag K
Kulkarni, Namrata B
Taur, Santosh R
Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study
title Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study
title_full Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study
title_fullStr Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study
title_full_unstemmed Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study
title_short Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study
title_sort safety of apixaban in indian patients undergoing elective total knee replacement or total hip replacement surgery: a multi-center, phase-iv study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511912/
https://www.ncbi.nlm.nih.gov/pubmed/34659763
http://dx.doi.org/10.1177/20503121211049962
work_keys_str_mv AT panchalhimanshu safetyofapixabaninindianpatientsundergoingelectivetotalkneereplacementortotalhipreplacementsurgeryamulticenterphaseivstudy
AT agasheabhijit safetyofapixabaninindianpatientsundergoingelectivetotalkneereplacementortotalhipreplacementsurgeryamulticenterphaseivstudy
AT sanchetiparagk safetyofapixabaninindianpatientsundergoingelectivetotalkneereplacementortotalhipreplacementsurgeryamulticenterphaseivstudy
AT kulkarninamratab safetyofapixabaninindianpatientsundergoingelectivetotalkneereplacementortotalhipreplacementsurgeryamulticenterphaseivstudy
AT taursantoshr safetyofapixabaninindianpatientsundergoingelectivetotalkneereplacementortotalhipreplacementsurgeryamulticenterphaseivstudy